Accordingly, treatment of animal models of brain tumor, pancreatic cancer, and hepatoblastoma with NK1R antagonists resulted in a significant reduction in Ki-67 positive cells [28–30], therefore supporting the previous evidence of an oncogenic effect of NK1R through enhancing tumor cell proliferation [16, 31]. Here, TACR1 is linked to neoplasm.